<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4571">
  <stage>Registered</stage>
  <submitdate>29/11/2007</submitdate>
  <approvaldate>29/11/2007</approvaldate>
  <nctid>NCT00565708</nctid>
  <trial_identification>
    <studytitle>Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers</studytitle>
    <scientifictitle>Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial</scientifictitle>
    <utrn />
    <trialacronym>ASCOLT</trialacronym>
    <secondaryid>SINGAPORE-ICR-02</secondaryid>
    <secondaryid>CDR0000577892</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - placebo
Treatment: drugs - Acetylsalicylic acid

Experimental: acetylsalicylic acid - 200mg OD for 3 years

Placebo Comparator: Placebo - 200mg OD for 3 years


Other interventions: placebo
Placebo Comparator

Treatment: drugs: Acetylsalicylic acid
Adjuvant Therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival</outcome>
      <timepoint>5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Male or female outpatient of = 18 years of age or = country's legal age for adult
             consent

          -  Dukes C colon cancer, high risk Dukes B colon cancer, Dukes B rectal cancer or Dukes C
             rectal cancer (see Appendix 1 for definition of High Risk Dukes B)

          -  Undergone complete resection of primary tumour

          -  Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy )

          -  Within 120 days of completion of standard therapy (surgery, chemotherapy ±
             radiotherapy)

          -  ECOG performance status 0 to 2

          -  Satisfactory haematological or biochemical functions (tests should be carried out
             within 8 weeks prior to randomisation): Results of clinical investigations carried out
             within 8 weeks prior to randomisation can be used in place of the required screening
             investigations. Patients with mild laboratory abnormalities can be included at the
             discretion by the site principal investigator, and after approval by ASCOLT Trial
             Management Group

          -  ANC = 1.0 x 109/L

          -  Platelets = 100 x 109/L

          -  Creatinine clearance = 30 mL/min

          -  Total bilirubin = 2.0 x the upper limit normal

          -  AST &amp; ALT = 5 x the upper limit normal

          -  Completed the following investigations

          -  Colonoscopy(or CT colonogram(within 16 months prior to randomization)

          -  Imaging of abdomen (CT or CT colonogram or MRI or PET or Ultrasound) within 16 months
             prior to randomization

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Pre-existing Familial adenomatous polyposis, inflammatory bowel disease or ulcerative
             colitis

          -  Active gastritis or active peptic ulcer

          -  History of continuous daily use of PPI more than 1 year prior to consent

          -  Gastrointestinal bleeding within the past one year

          -  Haemorrhagic diathesis (i.e. haemophilia)

          -  Uncontrolled hypertension (untreated systolic blood pressure &gt; 160 mmHg, or diastolic
             blood pressure &gt; 95 mmHg)

          -  History of recent cancers (except for colorectal cancers, non-melanoma skin cancers,
             basal cell carcinomas, squamous cell carcinomas) in the past 5 years

          -  History of stroke, coronary arterial disease, angina, or vascular disease

          -  Patients who are on current long term treatment (= 4 consecutive weeks) with Aspirin,
             NSAID or Cox-2 inhibitors

          -  History of erosive GERD or active erosive GERD on gastroscopy.

          -  Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin,
             clopidogrel, ticlopidine)

          -  Patient receiving active treatment of anticoagulants (i.e. warfarin, low molecular
             weight heparins)

          -  Pregnant, lactating, or not using adequate contraception

          -  Patient having known allergy to NSAID or Aspirin

          -  Unexplained rise of CEA (i.e. smoker with elevated CEA will not be excluded)

          -  Patient on other investigational drug

          -  Patients with HNPCC (Lynch Syndrome)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,NT,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Bankstown-Lidcombe Hospital Bankstown Cancer Centre - Bankstown</hospital>
    <hospital>Macarthur Cancer Therapy Centre - Campbelltown</hospital>
    <hospital>Chris O'Brien Lifehouse, Clinical Research Centre - Camperdown</hospital>
    <hospital>Coffs Harbour Health Campus North Coast Cancer Institute - Coffs Harbour</hospital>
    <hospital>Central Coast Cancer Centre Gosford Hospital - Gosford</hospital>
    <hospital>Newcastle private Hospital - New Lambton Heights</hospital>
    <hospital>Orange Health Service - Orange</hospital>
    <hospital>Port Macquarie Base Hospital North Coast Cancer Institute - Port Macquarie</hospital>
    <hospital>Northern Cancer Institute, St Leonards - St Leonards</hospital>
    <hospital>Northwest Cancer Centre Tamworth Hospital - Tamworth</hospital>
    <hospital>The Tweed Hospital - Tweed Heads</hospital>
    <hospital>Calvary Mater Newcastle Hospital - Waratah</hospital>
    <hospital>Royal Darwin Hospital - Tiwi</hospital>
    <hospital>Townsville Hospital - Douglas</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Monash Health Medical Oncology - East Bentleigh</hospital>
    <hospital>Barwon Health Andrew Love Cancer Centre - Geelong</hospital>
    <hospital>Austin Health Cancer Clinical Trials - Heidelberg</hospital>
    <hospital>Ballarat Regional Integrated Cancer Centre - North Ballarat</hospital>
    <hospital>Goulburn Valley Health - Shepparton</hospital>
    <hospital>St John of God Healthcare Southwest Oncology - Warrnambool</hospital>
    <hospital>Border Medical Oncology Research Unit - Wondonga</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>St John of God Hospital Subiaco - Subiaco</hospital>
    <postcode> - Bankstown</postcode>
    <postcode> - Campbelltown</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>2050 - Gosford</postcode>
    <postcode> - New Lambton Heights</postcode>
    <postcode> - Orange</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2340 - Tamworth</postcode>
    <postcode> - Tweed Heads</postcode>
    <postcode> - Waratah</postcode>
    <postcode> - Tiwi</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode> - Herston</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode>3350 - North Ballarat</postcode>
    <postcode>3630 - Shepparton</postcode>
    <postcode>3280 - Warrnambool</postcode>
    <postcode> - Wondonga</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shandong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhejiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nantong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Cochin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Trivandrum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Vellore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Yogyakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Penang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sarawak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sri Lanka</country>
      <state>Maharagama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>National Cancer Centre, Singapore</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Oxford</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Gastro-Intestinal Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>INDOX Cancer Research Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in
      patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in
      this patient population over placebo control. If indeed found to be beneficial, because
      aspirin is cheap and easy to administer, it will positively impact the lives of many
      individuals in Asia and globally.

      STUDY OBJECTIVE

      To assess the effectiveness of Aspirin against placebo control in patients with dukes C or
      high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall
      Survival (OS)

      Primary endpoints

        -  DFS among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer
           and rectal cancer patient sub-groups);

        -  DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer).

      Secondary endpoints

        -  Overall survival (OS) over 5 years

        -  DFS and OS in

             -  Chinese, Malay, Indian and other ethnic groups

             -  Resected high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer
                sub-groups, individually

             -  Compliant versus non-compliant subjects

             -  PIK3CA mutated tumors (where samples are available)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00565708</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Chia, MBBS, MRCP</name>
      <address>National Cancer Centre, Singapore</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>John Chia, MBBS, MRCP</name>
      <address />
      <phone>65-96536990</phone>
      <fax />
      <email>nmocwk@nccs.com.sg</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>